AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia
The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.
Primary source
ClinicalTrials.gov registry record, November 12, 2026
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Machine-summarized from the source above; not independently reported. How we use automation